**Core tip:** This is a retrospective study to evaluate the effect of *Helicobacter pylori* (*H. pylori*) status test and *H. pylori* eradication on the occurrence of metachronous gastric cancer (MGC) after endoscopic submucosal dissection (ESD) of early gastric cancer (EGC) and risk factors of MGC. *H. pylori* status test and *H. pylori* eradication seems to have no preventive effect on the occurrence of MGC after ESD for EGC. The risk factors of MGC were endoscopic gastric mucosal atrophy in *H. pylori* tested group alone and intestinal metaplasia in all patients.

INTRODUCTION
============

Endoscopic resection (ER) including endoscopic mucosal resection and endoscopic submucosal dissection (ESD) is a recognized as one of treatment options for curative resection of early gastric cancer (EGC) without simultaneous concomitant lymph node metastasis\[[@B1]-[@B4]\]. Unlike surgery of EGC, ER preserves most part of the stomach and this leads to increased risk of metachronous gastric cancer (MGC) development in residual gastric mucosa\[[@B5]\]. As more EGCs are treated with ER recently, identifying risk factors of MGC development after ER of EGC is important.

*Helicobacter pylori* (*H. pylori*) infection is related to the development of gastritis, atrophy, intestinal metaplasia, dysplasia, and gastric cancer\[[@B6]-[@B9]\]. Among dietary, environmental, and genetic risk factors of gastric cancer, *H. pylori* is classified as a Group 1 or definite carcinogen for gastric cancer by the World Health Organization\[[@B10]\]. In previous reports, the odds for development of gastric cancer reported to increase by 2-4 folds in the patients with *H. pylori* infection\[[@B11],[@B12]\].

The effect of *H. pylori* eradication on development of MGC after ER of EGC is still on debate. A study of 132 patients who underwent ER for EGC and showed positive *H. pylori* serologic test demonstrated that *H. pylori* eradication inhibited the growth of new gastric cancer\[[@B13]\] and a retrospective study of 283 patients with *H. pylori* infection at time of ESD for EGC showed that failure of *H. pylori* eradication was a risk factor of MGC development\[[@B5]\]. However, a study of 1258 patients who underwent ESD for EGC reported that the incidence rate of MGC was not significantly different between patients with or without *H. pylori* eradication\[[@B14]\] and a retrospective study of 268 patients with a 5-year follow-up reported that *H. pylori* eradication after ER for EGC did not significantly reduced the incidence of MGC\[[@B15]\]. Studies about the effect of *H. pylori* status test on development of MGC after ER of EGC has been scarce.

The aims of this study were to investigate the effect of *H. pylori* status test and *H. pylori* eradication on the occurrence of MGC after ESD of EGC and risk factors of MGC.

MATERIALS AND METHODS
=====================

Patients
--------

The medical records of 599 patients with 611 lesions who underwent ESD for EGC from January 2005 to January 2015 at Yeungnam university hospital were retrospectively reviewed. Exclusion criteria of the present study were as follows: additional gastrectomy due to a non-curative ESD of EGC and short-term follow-up duration (\< 6 mo) and a total of 166 patients with 170 lesions were excluded from the present study. Finally, 433 patients with 441 lesions were included for analysis. Baseline clinical characteristics of the patients, characteristics and histology findings of EGC, performance of *H. pylori* status test and *H. pylori* eradication and occurrence of MGC were analyzed. Institutional review board approval was obtained for this study (2016-06-035).

H. pylori status and follow-up
------------------------------

Patients were divided into two groups; the *H. pylori* tested group (*n =* 257) and the *H. pylori* non-tested group (*n =* 176) based on performance of *H. pylori* status test after ESD of EGC. Patients in the *H. pylori* tested group were further divided into three subgroups; the *H. pylori* negative subgroup, the *H. pylori* eradicated subgroup, and the *H. pylori* persistent subgroup (Figure [1](#F1){ref-type="fig"}).

![Study flowchart. EGC: Early gastric cancer; ESD: Endoscopic submucosal dissection; *H. pylori*: *Helicobacter pylori*.](WJG-22-9794-g001){#F1}

Among patients with positive *H. pylori* test results, patients who agreed to treat *H. pylori* infection received *H. pylori* eradication. The regimen for first-line *H. pylori* treatment was triple therapy with amoxicillin 1000 mg, clarithromycin 500 mg, and a proton-pump inhibitor (pantoprazole 40 mg, eomeprazole 40 mg, lansoprazole 30 mg or rabeprazole 20 mg) all twice daily for a week. The regimen for second-line *H. pylori* treatment was a quadruple therapy with metronidazole 500 mg (3 times daily), tetracycline 500 mg (4 times daily), tripotassium dicitrato bismuthate 300 mg (4 times daily), and a proton-pump inhibitor (twice daily) for 10-14 d. Eradication was confirmed by histology or rapid urase test at scheduled esophagogastroduodenoscopy (EGD) follow-up after ESD or urea breathing test. After ESD, scheduled EGD was performed at 2 or 3, 6, and 12 mo, and annually thereafter.

The presence of gastric mucosal atrophy was assessed through EGD and presence of intestinal metaplasia through histology. MGC was defined as the development of new gastric cancer at a previously uninvolved site in the stomach after the 6 mo following ESD. MGC was confirmed by histology of biopsy specimens. Incidences of MGC was compared according to performance of *H. pylori* status test and among the *H. pylori* eradicated, persistent and negative group and risk factors of MGC were analyzed.

Statistical analysis
--------------------

Results are presented as means and standard deviations or as medians and ranges. The *χ^2^* or Fisher's exact test and one-way analysis of variance test or the Student's *t*-test were used to compare categorical and continuous variables, respectively. The log-rank test was used for to compare group incidence rates. Univariate and multivariate Cox proportional hazard regression analyses were used to identify independent risk factors associated with MGC development. Covariates with *P* values of \< 0.05 by univariate analyses were entered into multivariate analysis. Statistical analyses of the data were performed using SPSS 20 (IBM SPSS, Chicago, IL, United States). Statistical significance was accepted for *P* values \< 0.05.

RESULTS
=======

Baseline characteristics of the patients
----------------------------------------

Mean age of the 433 patients included in the present study was 67.02 years and 325 (75.1%) patients were male and 108 (24.9%), female. Median follow-up duration after ESD of EGC was 30.00 mo (range, 6-107 mo).

Among 257 patients of the *H. pylori* tested group, 162 (63.0%) patients showed positive result for *H. pylori* test and 95 (37.0%) patients, negative. Of these 162 patients with positive result of *H. pylori* test, *H. pylori* eradication was done in 139 patients and eradication was successful in 120 (86.3%) patients. Ninety-five patients without *H. pylori* infection were classified as the *H. pylori*-negative subgroup, 120 patients with successful *H. pylori* eradication as the *H. pylori*-eradicated subgroup, and 42 patients (19 patients in whom *H. pylori* eradication failed and 23 patients not treated for *H. pylori* infection) as the *H. pylori*-persistent subgroup (Figure [1](#F1){ref-type="fig"}). The mean age of *H. pylori* tested group was 66.61 years and 189 (73.5%) patients were male. Patients in the *H. pylori*-eradicated subgroup were significantly younger than patients in the *H. pylori*-negative and *H. pylori*-persistent subgroups (*P \<* 0.05). The mean follow-up duration was not significantly different between three subgroups (*P \>* 0.05). Endoscopic mucosal atrophy and intestinal metaplasia were significantly more prevalent in the *H. pylori*-negative subgroup than the other two subgroups (*P \<* 0.05). The location and macroscopic type of primary gastric cancer were not significantly different between three subgroups (*P \>* 0.05). The *H. pylori*-persistent subgroup had significantly less differentiated cancers than other two subgroups (*P* = 0.032) (Table [1](#T1){ref-type="table"}).

###### 

Baseline characteristics of patients in the *Helicobacter pylori* tested group *n* (%)

                                               ***H. pylori***   ***H. pylori***   ***H. pylori***   ***P* value**
  -------------------------------------------- ----------------- ----------------- ----------------- ---------------
  Sex                                                                                                
  Male                                         74 (77.9)         29 (69.0)         86 (71.7)         0.454
  Female                                       21 (22.1)         13 (31.0)         34 (28.3)         
  Age, mean (SD)                               68.65 (8.86)      67.31 (9.12)      64.76 (10.10)     0.011
  Follow-up period (mo), mean (SD)             36.18 (± 26.74)   33.29 (± 25.93)   32.78 (± 23.72)   0.149
  Endoscopic mucosal atrophy                   50 (52.6)         8 (19.0)          25 (20.8)         \< 0.001
  Intestinal metaplasia                        63 (66.3)         18 (42.9)         32 (26.7)         \< 0.001
  Location of primary cancer                                                                         
  Upper                                        10 (10.5)         5 (11.9)          10 (8.3)          0.577
  Middle                                       36 (37.9)         14 (33.3)         35 (29.2)         
  Lower                                        49 (51.6)         23 (54.8)         75 (62.5)         
  Macroscopic type of primary cancer                                                                 
  Elevated                                     40 (42.1)         122 (8.6)         57 (47.5)         0.177
  Flat                                         13 (13.7)         5 (11.9)          9 (7.5)           
  Depressed                                    42 (37.0)         25 (59.5)         54 (45.0)         
  Diameter of primary cancer (cm), mean (SD)   14.24 (7.31)      13.83 (6.22)      13.67 (6.90)      0.978
  Histology of primary cancer                                                                        
  Differentiated                               93 (97.9)         38 (90.5)         118 (98.3)        0.032
  Undifferentiated                             2 (2.1)           4 (9.5)           2 (1.7)           
  ESD criteria                                                                                       
  Absolute                                     73 (76.8)         33 (78.6)         95 (79.2)         0.636
  Expended                                     18 (18.9)         5 (11.9)          19 (15.8)         
  Beyond expanded                              4 (4.2)           4 (9.5)           6 (5.0)           
  Depth of primary cancer                                                                            
  Mucosa                                       89 (93.7)         40 (95.2)         111 (92.5)        0.819
  Submucosa                                    6 (6.3)           2 (4.8)           9 (7.5)           
  Metachronous cancer recurrence               7 (7.4)           1 (2.4)           3 (2.5)           0.173

ESD: Endoscopic submucosal dissection; *H. pylori*: *Helicobacter pylori*.

The mean age and follow-up duration were not significantly different between the *H. pylori* tested and the *H. pylori* non-tested groups (*P \>* 0.05). Endoscopic mucosal atrophy and intestinal metaplasia was significantly more frequent in the *H. pylori* tested group than in the *H. pylori* non-tested group, and location of primary gastric cancer location was significantly lower in the *H. pylori* tested group than the *H. pylori* non-tested group (*P* \< 0.05). In addition, the *H. pylori* non-tested group had more elevated lesions than the *H. pylori* tested group and the *H. pylori* tested group had more depressed lesions than the *H. pylori* non-tested group (*P \<* 0.05) (Table [2](#T2){ref-type="table"}).

###### 

Baseline characteristics of patients according to performance of *Helicobacter pylori* status test *n* (%)

                                               ***H. pylori* tested group**   ***H. pylori* non-tested group**   ***P* value**
  -------------------------------------------- ------------------------------ ---------------------------------- ---------------
  Sex                                                                                                            
  Male                                         189 (73.5)                     136 (77.3)                         0.378
  Female                                       68 (26.5)                      40 (22.7)                          
  Age, mean (SD)                               66.61 (9.63)                   67.60 (10.03)                      0.303
  Follow-up period (mo), mean (SD)             34.12 (25.19)                  33.31 (18.11)                      0.699
  Endoscopic mucosal atrophy                   83 (32.3)                      12 (6.8)                           \< 0.001
  Intestinal metaplasia                        113 (44.0)                     14 (8.0)                           \< 0.001
  Location of primary cancer                                                                                     
  Upper                                        25 (9.7)                       12 (6.8)                           
  Middle                                       85 (33.1)                      37 (21.0)                          0.006
  Lower                                        147 (57.2)                     127 (72.2)                         
  Macroscopic type of primary cancer                                                                             
  Elevated                                     109 (42.4)                     95 (54.0)                          
  Flat                                         27 (10.5)                      24 (13.6)                          0.009
  Depressed                                    121 (47.1)                     57 (32.4)                          
  Diameter of primary cancer (cm), mean (SD)   13.91 (6.93)                   14.30 (5.74)                       0.540
  Histology of primary cancer                                                                                    
  Differentiated                               249 (96.9)                     171 (97.2)                         
  Undifferentiated                             8 (3.1)                        5 (2.8)                            0.871
  ESD criteria                                                                                                   
  Absolute                                     201 (78.2)                     142 (80.7)                         0.234
  Expended                                     42 (16.3)                      20 (11.4)                          
  Beyond expanded                              14 (5.4)                       14 (8.0)                           
  Depth of primary cancer                                                                                        
  Mucosa                                       240 (93.4)                     161 (91.5)                         0.456
  Submucosa                                    17 (6.6)                       15 (8.5)                           
  Metachronous cancer recurrence               11 (4.3)                       4 (2.3)                            0.262

ESD: Endoscopic submucosal dissection; *H. pylori*: *Helicobacter pylori*.

Development of MGC according to H. pylori status
------------------------------------------------

Among total 433 patients, MGC developed in 15 (3.5%) patients; 11 (4.3%) patients in the *H. pylori* tested group and 4 (2.3%) in the *H. pylori* non-tested group without significant difference (*P* = 0.262) (Table [2](#T2){ref-type="table"}).

Among 11 patients who developed MGC in the *H. pylori* tested group, MGC developed in 7 (7.4%) patients of the *H. pylori*-negative subgroup, 3 (2.5%) patients of the *H. pylori*-eradicated subgroup, and 1 (2.4%) patient of the *H. pylori*-persistent subgroup. Although the incidence of MGC was higher in the *H. pylori*-negative subgroup than other two subgroups, statistical significance was not found among the three subgroups (*P* = 0.173) (Table [1](#T1){ref-type="table"}).

Characteristics of patients with MGC
------------------------------------

Mean age of patients with MGC was 68.93 years and all patients with MGC were male. No significant differences were observed between MGC group and non-MGC group in terms of age, primary cancer location, and primary lesion size (*P \>* 0.05), and mean follow-up duration was not significantly different between two groups (*P* = 0.752). Endoscopic mucosal atrophy and intestinal metaplasia were significantly more prevalent in patients with MGC than without (*P \<* 0.05) (Table [3](#T3){ref-type="table"}).

###### 

Comparisons of clinical characteristics between patients with or without metachronous gastric cancer in all patients *n* (%)

                                               **Non-metachronous gastric cancer group (*n* = 418)**   **Metachronous gastric cancer group (*n* = 15)**   ***P* value**
  -------------------------------------------- ------------------------------------------------------- -------------------------------------------------- ---------------
  Sex                                                                                                                                                     
  Male                                         310 (74.2)                                              15 (100)                                           0.028
  Female                                       108 (25.8)                                              0 (0)                                              
  Age, mean (SD)                               66.95 (9.82)                                            68.93 (9.35)                                       0.441
  Location of primary cancer                                                                                                                              
  Upper                                        35 (8.4)                                                2 (13.3)                                           0.163
  Middle                                       115 (27.5)                                              7 (46.7)                                           
  Lower                                        268 (64.1)                                              6 (40.0)                                           
  Lesion size (cm), mean (SD)                  14.01 (6.10)                                            15.60 (13.48)                                      0.350
  Endoscopic mucosal atrophy                   87 (20.8)                                               8 (53.3)                                           0.003
  Intestinal metaplasia                        117 (28.0)                                              10 (66.7)                                          0.001
  Histology of undifferentiated type           12 (2.9)                                                1 (6.7)                                            0.397
  SM invasion                                  31 (7.4)                                                1 (6.7)                                            0.913
  Non-performance of *H. pylori* status test   172 (41.1)                                              4 (26.7)                                           0.262
  Follow-up period (mo), mean period (SD)      33.72 (22.58)                                           35.60 (22.68)                                      0.752

SM: Submucosa; *H. pylori*: *Helicobacter pylori*.

In the *H. pylori* tested group, age, primary cancer location, and lesion size were not significantly different between patients with or without MGC and follow-up duration was similar between two groups (33.72 ± 23.64 *vs* 34.13 ± 25.30, *P* = 0.997). The patient with MGC showed higher proportion of negative *H. pylori* status than without (63.6% *vs* 35.8%, *P* = 0.061). However, endoscopic mucosal atrophy and intestinal metaplasia were observed significantly more in patients with MGC than without (72.7% *vs* 30.5%, *P* = 0.003 and 81.8% *vs* 42.3%, *P* = 0.010) (Table [4](#T4){ref-type="table"}).

###### 

Comparisons of the clinical characteristics of patients with or without matachronous gastric cancer in the *Helicobacter pylori* tested group *n* (%)

                                       **Non-metachronous gastric cancer group (*n* = 246)**   **Metachronous gastric cancer group (*n* = 11)**   ***P* value**
  ------------------------------------ ------------------------------------------------------- -------------------------------------------------- ---------------
  Sex                                                                                                                                             
  Male                                 178 (72.4)                                              11 (100)                                           0.042
  Female                               68 (29.6)                                               0 (0)                                              
  Age, mean (SD)                       66.44 (9.66)                                            70.45 (8.52)                                       0.177
  Location of primary cancer                                                                                                                      
  Upper                                24 (9.8)                                                1 (9.1)                                            0.290
  Middle                               79 (32.1)                                               6 (54.5)                                           
  Lower                                143 (58.1)                                              4 (36.4)                                           
  Lesion size (cm), mean (SD)          13.75 (6.32)                                            17.36 (15.45)                                      0.458
  Endoscopic mucosal atrophy           75 (30.5)                                               8 (72.7)                                           0.003
  Intestinal metaplasia                104 (42.3)                                              9 (81.8)                                           0.010
  Histology of undifferentiated type   8 (3.3)                                                 0 (0)                                              0.543
  SM invasion                          16 (6.5)                                                1 (9.1)                                            0.736
  Persistent *H. pylori* infection     41 (16.7)                                               1 (9.1)                                            0.173
  *H. pylori* negative                 88 (35.8)                                               7 (63.6)                                           0.061
  Follow-up period (mo), mean (SD)     34.13 (25.30)                                           33.72 (23.64)                                      0.958

SM: Submucosa; *H. pylori*: *Helicobacter pylori*.

Factors associated with the development of MGC
----------------------------------------------

In the *H. pylori* test group, endoscopic mucosal atrophy and intestinal metaplasia were found to be significantly associated with the development of MGC by univariate analysis (*P \<* 0.05). Multivariate Cox proportional hazard regression analysis revealed an association with MGC development only for endoscopic mucosal atrophy (HR = 6.080, *P* = 0.009) (Table [5](#T5){ref-type="table"}).

###### 

Results of univariate and multivariate analysis for factors associated with the development of metachronous gastric cancer in the *Helicobacter pylori* tested group

                                       **Univariate analysis**   **Multivariate analysis**                                  
  ------------------------------------ ------------------------- --------------------------- ------- ------- -------------- -------
  Age ≥ 65 yr                          1.736                     0.449-6.705                 0.424                          
  Endoscopic mucosal atrophy           6.080                     1.569-23.556                0.009   6.080   1.569-23.556   0.009
  Intestinal metaplasia                6.144                     1.300-29.033                0.022   2.654   0.400-17.621   0.312
  Histology of undifferentiated type   0.000                     0.000                       0.999                          
  SM invasion                          1.437                     0.173-11.942                0.737                          
  *H. pylori* negative                 3.142                     0.895-11.031                0.074   1.638   0.426-6.299    0.473
  *H. pylori* eradication              0.413                     0.107-1.595                 0.200                          

SM: Submucosa; *H. pylori*: *Helicobacter pylori*.

In all patients, endoscopic mucosal atrophy and intestinal metaplasia were significantly associated with MGC development in univariate analysis and multivariate Cox proportional hazard regression analysis showed an association between intestinal metaplasia and MGC development (HR = 4.67, *P* = 0.006) (Table [6](#T6){ref-type="table"}).

###### 

Results of univariate and multivariate analysis for factors associated with the development of metachronous gastric cancer in all patients

                                       **Univariate analysis**   **Multivariate analysis**                                  
  ------------------------------------ ------------------------- --------------------------- ------- ------- -------------- -------
  Age ≥ 65 yr                          1.317                     0.442-3.923                 0.620                          
  Endoscopic mucosal atrophy           4.348                     1.535-12.320                0.006   1.966   0.526-7.351    0.315
  Intestinal metaplasia                5.145                     1.722-15.373                0.003   5.145   1.722-15.373   0.003
  Histology of undifferentiated type   2.417                     0.293-19.902                0.412                          
  SM invasion                          0.892                     0.113-7.007                 0.913                          
  *H. pylori* non-tested               0.520                     0.163-1.660                 0.270                          

SM: Submucosa; *H. pylori*: *Helicobacter pylori*.

DISCUSSION
==========

In the present study, 15 (3.5%) of the 433 patients developed MGC after ESD for EGC and this result was comparable with previous reports\[[@B16],[@B17]\]. MGC occurs more frequently after ER for EGC than surgery (2.5%-14% *vs* 1.8%-5%)\[[@B16]-[@B19]\]. This increased risk of MGC after ER for EGC can be partly explained by higher proportion of salvaged stomach in ER than surgery. The mean duration of MGC development from ESD of EGC was 35.6 mo and 3 patients developed MGC after 5 years from initial ESD of EGC. A retrospective study of 1526 patients who underwent ESD for EGC reported that 5-year, 7-year, and 10-year cumulative incidence functions of MGC were 9.5%, 13.1%, and 22.7%, respectively\[[@B20]\]. Meticulous examination at surveillance EGD is needed in patients who underwent ER for EGC and EGD should be done with schedule. Further studies are needed to find optimal schedule for surveillance EGD after ER of EGC.

The chronic inflammation of stomach induced by *H. pylori* infection may lead to mucosal atrophy, intestinal metaplasia, and dysplasia, and risk of developing gastric cancer is increased in patients exhibiting such histologic changes of stomach\[[@B21],[@B22]\]. An animal study has reported that *H. pylori* eradication decreased polyp formation, inflammatory cell infiltration, and cellular proliferation in the gastric mucosa and suggested that *H. pylori* eradication could diminish mucosal alterations related to gastric carcinogenesis\[[@B23]\]. However, the preventative effect of *H. pylori* eradication on MGC development after ESD for EGC is still on debate. In the present study, the incidence of MGC after ESD of EGC was not significantly different between the *H. pylori*-negative subgroup, the *H. pylori*-eradicated subgroup, and the *H. pylori*-persistent subgroups and *H. pylori* eradication had no preventive effect on the development of MGC after ESD of EGC. However, the *H. pylori*-negative subgroup showed higher tendency towards development of MGC after ESD of EGC than other two subgroups without statistical significance and this might be due to significantly higher proportion of endoscopic mucosal atrophy and intestinal metaplasia in the *H. pylori*-negative subgroup than other two subgroups. The higher proportion of patients with intestinal metaplasia in the *H. pylori*-negative subgroup might have led to false negative result in the *H. pylori* status test.

In the present study, the development of MGC was compared according to performance of *H. pylori* status test and no significant difference in the development of MGC after ESD of EGC was observed between two groups during follow-up. As *H. pylori* status test and *H. pylori* eradication failed to show preventive effect on development of MGC after ESD of EGC in the present study, further large scaled prospective studies are needed to clarify the effect of *H. pylori* status test and *H. pylori* eradication on MGC development in patients who underwent ESD for EGC.

The mucosal atrophy of stomach has been previously reported to contribute to the development of MGC\[[@B15]\]. A study of 100 patients who underwent ESD for EGC reported that the frequency of severe atrophy assessed by histology was higher in the group that developed cancer compared to the group that did not and severity of atrophy was the only independent risk factor of MGC development after *H. pylori* eradication\[[@B24]\]. In the present study, endoscopic mucosal atrophy and intestinal metaplasia were observed more frequently in patients with MGC than in those without. Furthermore, multivariate analysis showed that endoscopic mucosal atrophy in the *H. pylori* tested group and intestinal metaplasia in all patients as a risk factor of MGC development after ESD of EGC.

The effect of *H. pylori* eradication on improvement of mucosal atrophy remains unclear in previous studies\[[@B25]-[@B28]\]. A study of 544 patients with EGC reported the preventive effect of *H. pylori* eradication on development of MGC after ER of EGC even in patients with corpus atrophy\[[@B29]\]. However, a large-scale, randomized, and controlled study about 1630 healthy carriers of *H. pylori* infection in China reported that the *H. pylori* carriers with precancerous state defined as presence of mucosal atrophy, intestinal metaplasia, or dysplasia had no preventive effect of *H. pylori* eradication on development of gastric cancer\[[@B30]\]. The ineffectiveness of *H. pylori* eradication on MGC development after ESD of EGC in the present study might have been due to irreversible mucosal atrophic change. Further studies to clarify the effect of *H. pylori* eradication on MGC development according to status of gastric mucosa is needed.

In the present study, all patients who developed MGC were male. A previous study reported that male gender was one of risk factors for MGC development of ESD of EGC\[[@B20]\]. However, male gender was not found as a risk factor of MGC in the present study and further study with longer follow up duration is needed to clarify the effect of gender on development of MGC after ESD of EGC.

The present study has several limitations. First, its retrospective nature study makes selection bias inevitable, as was reflected by differences in the baseline characteristics of patients including atrophy and intestinal metaplasia status. Second, relatively small patients of MGC were included for the analysis, and if more patients with MGC had been included, it is possible that *H. pylori* eradication might have been found to influence MGC development. Third, determination of *H. pylori* infection status was inadequate, and thus, false negative and positive results were possibly included. Forth, we did not examine other causes of mucosal atrophy.

In conclusion, *H. pylori* eradication and *H. pylori* status test seems to have no preventive effect on the development of MGC after ESD for EGC. The risk factors of MGC development after ESD of EGC were gastric mucosal atrophy in *H. pylori* tested group and intestinal metaplasia in all patients.
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Research frontiers
------------------

Studies about the preventive role *of H. pylori* eradication in the development of MGC after ER of EGC showed conflicting results.

Innovations and breakthroughs
-----------------------------

In this study, *H. pylori* status test and *H. pylori* eradication seems to have no preventive effect on the development of MGC after ESD for EGC. The risk factors of MGC development were endoscopic gastric mucosal atrophy in *H. pylori* tested group alone and intestinal metaplasia in all patients.
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Due to retrospective nature of the study, further prospective studies to clarify the effect of *H. pylori* status test and *H. pylori* eradication on the occurrence of MGC after ESD of EGC and risk factors of MGC are needed.
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Early gastric cancer: An adenocarcinoma that is restricted to the mucosa or submucosa of stomach, irrespective of lymph node metastasis.
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